Programs
Our fearless pursuit of science, guided by in-depth translational research, aims to address unmet needs for patients with limited treatment options.
Our fearless pursuit of science, guided by in-depth translational research, aims to address unmet needs for patients with limited treatment options.
Checkpoint inhibitors (CPI) have revolutionized the cancer treatment landscape by helping many people with different types of cancer live longer. Over time, patients have progression of their disease on or after receiving CPI therapy, leaving them with few remaining treatment options.
Our research is investigating whether novel combination approaches will augment CPI therapy by targeting key pathways and cell types responsible for tumor growth and immune suppression in the tumor microenvironment.
MRTX1719 is an investigational, internally discovered synthetic lethal PRMT5 inhibitor for the treatment of methylthioadenosine phosphoylase (MTAP)-deleted cancers.